Variations in transfection efficiency of VEGF165 and VEGF121-cDNA -: Its effects on proliferation and migration of human endothelial cells

被引:2
作者
Djurovic, S [1 ]
Kristansen, H
Sletten, M
Halvorsen, K
Berg, K
机构
[1] Ullevaal Univ Hosp, Dept Med Genet, Oslo, Norway
[2] Univ Oslo, Inst Med Genet, Oslo 3, Norway
关键词
VEGF; transfection efficiency; smooth muscle cells; Fu-GENE; 6; proliferation; migration;
D O I
10.1385/MB:26:1:7
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 [生物化学与分子生物学]; 081704 [应用化学];
摘要
Little is known about the expression pattern of vascular endothelial growth factor (VEGF) among smooth muscle cells of different arterial regions. Therefore, we have conducted studies aimed at increasing expression of VEGF in cultured human smooth muscle cells (SMCs), from different sites: aorta, umbilical artery, and coronary artery. Two plasmids harboring human VEGF(121) and VEGF(165) isoforms, respectively, were constructed and lipotransfected into vascular SMCs, using the Fu-GENE 6. Extensive optimization of transfection conditions were performed prior to this. Different basal levels of VEGF were observed between celf'types: from 0.51-0.95 pg/mL/mug protein in umbilical artery, through 2.32-2.39 pg/mL/mug protein in coronary artery, to 5.45-7.52 pg/mL/mug protein in aortic SMCs. Significant differences in responses to transfection were also observed: The increase in VEGF. production was most pronounced in umbilical artery SMCs (e.g, with 4 mug VEGF(121)-cDNA/in the wells)-an approximate 600-fold as opposed to an 18-fold increase in aortic SMCs and a 29-fold increase in coronary artery SMCs. In addition, we observed significant increases in proliferation rate of aortic and coronary endothelial cells (ECs), after incubation with conditioned medium from VEGF-transfected SMCs. Observed changes differed in relation to cell origin and isoform.
引用
收藏
页码:7 / 16
页数:10
相关论文
共 29 条
[1]
BATTEGAY EJ, 1995, J MOL MED, V73, P333
[2]
VECTOR METHYLATION INHIBITS TRANSCRIPTION FROM THE SV40 EARLY PROMOTER [J].
BRYANS, M ;
KASS, S ;
SEIVWRIGHT, C ;
ADAMS, RLP .
FEBS LETTERS, 1992, 309 (01) :97-102
[3]
FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition [J].
Cross, MJ ;
Claesson-Welsh, L .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2001, 22 (04) :201-207
[4]
Cytotoxicity issues pertinent to lipoplex-mediated gene therapy in-vivo [J].
Dass, CR .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 2002, 54 (05) :593-601
[5]
Dulak J, 2000, VASC MED, V5, P33
[6]
DVORAK HF, 1995, AM J PATHOL, V146, P1029
[7]
Ferrara N, 1997, ENDOCR REV, V18, P1
[8]
A placebo-controlled study of liposome-mediated gene transfer to the nasal epithelium of patients with cystic fibrosis [J].
Gill, DR ;
Southern, KW ;
Mofford, KA ;
Seddon, T ;
Huang, L ;
Sorgi, F ;
Thomson, A ;
MacVinish, LJ ;
Ratcliff, R ;
Bilton, D ;
Lane, DJ ;
Littlewood, JM ;
Webb, AK ;
Middleton, PG ;
Colledge, WH ;
Cuthbert, AW ;
Evans, MJ ;
Higgins, CF ;
Hyde, SC .
GENE THERAPY, 1997, 4 (03) :199-209
[9]
Selective binding of VEGF(121) to one of the three vascular endothelial growth factor receptors of vascular endothelial cells [J].
GitayGoren, H ;
Cohen, T ;
Tessler, S ;
Soker, S ;
Gengrinovitch, S ;
Rockwell, P ;
Klagsbrun, M ;
Levi, BZ ;
Neufeld, G .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (10) :5519-5523
[10]
VASCULAR SYSTEM DEFECTS AND NEURONAL APOPTOSIS IN MICE LACKING RAS GTPASE-ACTIVATING PROTEIN [J].
HENKEMEYER, M ;
ROSSI, DJ ;
HOLMYARD, DP ;
PURI, MC ;
MBAMALU, G ;
HARPAL, K ;
SHIH, TS ;
JACKS, T ;
PAWSON, T .
NATURE, 1995, 377 (6551) :695-701